Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  OTC Bulletin Board  >  IntelGenx Technologies Corp.    IGX

 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2016 6,60 M
EBIT 2016 0,60 M
Net income 2016 0,25 M
Debt 2016 -
Yield 2016 -
Sales 2017 5,35 M
EBIT 2017 -1,47 M
Net income 2017 -1,34 M
Debt 2017 -
Yield 2017 -
P/E ratio 2016 156,49
P/E ratio 2017
Capi. / Sales2016 7,66x
Capi. / Sales2017 9,46x
Capitalization 50,6 M
More Financials
Company
IntelGenx Technologies Corp. operates as a drug delivery company.It focuses on the development of novel, orally administered drug delivery products based on its proprietary oral drug delivery technologies.The company is a provider of product development services for the pharmaceutical industry,... 
Sector
Pharmaceuticals
Calendar
03/14Earnings Release
More about the company
Surperformance© ratings of IntelGenx Technologies Cor
Trading Rating : - Investor Rating :
More Ratings
Latest news on INTELGENX TECHNOLOGIES COR
12/01 INTELGENX TECHNOLOGIES CORP. (OTCMKT : IGXT) Files An 8-K Other Events
12/01 INTELGENX TECHNOLOGIES CORP. : Other Events (form 8-K)
12/01 INTELGENX TECHNOLOGIES : Strengthens Partnership with Chemo Group by Signing a C..
11/23 ELI LILLY AND : Intelgenx secures a license for tadalafil erectile dysfunction d..
11/21 INTELGENX TECHNOLOGIES CORP. : Other Events (form 8-K)
11/21 INTELGENX TECHNOLOGIES : Secures a License For Tadalafil Erectile Dysfunction Do..
11/14 SWK : Intelgenx reports profitable third quarter with increased growth in revenu..
11/10 INTELGENX TECHNOLOGIES : posts 3Q profit
11/10 INTELGENX TECHNOLOGIES CORP. : Management's Discussion and Analysis of Financial..
11/10 INTELGENX TECHNOLOGIES CORP. : Other Events (form 8-K)
More news
Sector news : Generic Pharmaceuticals
01:25aDJJOHNSON & JOHNSON : Boosts Actelion Bid -Bloomberg
12/02 Pharma execs weigh in on possible changes under Trump
12/02DJJOHNSON & JOHNSON : Jury Orders Johnson & Johnson to Pay More Than $1 Billion in..
12/01DJValeant Deal Talks Collapse Over Price -- WSJ
12/01DJCSL : Eyes Biggest Undertaking Yet in Heart Therapy Trial
More sector news : Generic Pharmaceuticals
Advertisement
Income Statement Evolution
More Financials
Consensus 
Mean consensus BUY
Number of Analysts 1
Average target price 1,50 $
Spread / Average Target 92%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Horst G. Zerbe Chairman, President & Chief Executive Officer
André Godin Chief Financial Officer & Executive Vice President
Nadine Paiement Director-Research & Development
Bernd Josef Melchers Independent Director
John Archibald Troup Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
INTELGENX TECHNOLOGIES..51
SUN PHARMACEUTICAL IND..-11.86%25 404
OTSUKA HOLDINGS CO LTD4.22%22 196
ONO PHARMACEUTICAL CO...-41.99%13 002
ASPEN PHARMACARE HOLDI..-8.64%9 268
SHANGHAI FOSUN PHARMAC..-1.83%7 929
More Results